Search Results - "Stephenson, Joe J."

Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer by Petrylak, Daniel P., Kantoff, Philip, Vogelzang, Nicholas J., Mega, Anthony, Fleming, Mark T., Stephenson, Joe J., Frank, Richard, Shore, Neal D., Dreicer, Robert, McClay, Edward F., Berry, William R., Agarwal, Manish, DiPippo, Vincent A., Rotshteyn, Yakov, Stambler, Nancy, Olson, William C., Morris, Stephen A., Israel, Robert J.

“…Background Prostate‐specific membrane antigen (PSMA) is a well‐characterized target that is overexpressed selectively on prostate cancer cells. PSMA…”
Get full text

Phase 1 dose‐escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma by Rini, Brian I., Stein, Mark, Shannon, Pat, Eddy, Simantini, Tyler, Allison, Stephenson, Joe J., Catlett, Lorie, Huang, Bo, Healey, Diane, Gordon, Michael

“…BACKGROUND: On the basis of potential additive or synergistic immunostimulatory antitumor effects, in this phase 1 study, the authors evaluated the combination…”
Get full text

A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma by Murray Stewart, Tracy, Von Hoff, Daniel, Fitzgerald, Michael, Marton, Laurence J., Becerra, Carlos H. Roberto, Boyd, Thomas E., Conkling, Paul R., Garbo, Lawrence E., Jotte, Robert M., Richards, Donald A., Smith, David A., Stephenson, Joe J., Vogelzang, Nicholas J., Wu, Hillary H., Casero, Robert A.

“…Purpose Polyamines are absolutely essential for maintaining tumor cell proliferation. PG-11047, a polyamine analogue, is a nonfunctional competitor of the…”
Get full text

A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer by Adjei, Alex A, Richards, Donald A, El-Khoueiry, Anthony, Braiteh, Fadi, Becerra, Carlos H R, Stephenson, Jr, Joe J, Hezel, Aram F, Sherman, Morris, Garbo, Lawrence, Leffingwell, Diane P, Iverson, Cory, Miner, Jeffrey N, Shen, Zancong, Yeh, Li-Tain, Gunawan, Sonny, Wilson, David M, Manhard, Kimberly J, Rajagopalan, Prabhu, Krissel, Heiko, Clendeninn, Neil J

“…To assess the safety and tolerability of the small-molecule allosteric MEK inhibitor refametinib combined with sorafenib, in patients with advanced solid…”
Get full text

The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors by Rosen, Lee S, Lipton, Lara, Price, Timothy J, Belman, Neil D, Boccia, Ralph V, Hurwitz, Herbert I, Stephenson, Jr, Joe J, Wirth, Lori J, McCoy, Sheryl, Hei, Yong-Jiang, Hsu, Cheng-Pang, Tebbutt, Niall C

“…Gallbladder toxicity, including cholecystitis, has been reported with motesanib, an orally administered small-molecule antagonist of VEGFRs 1, 2 and 3; PDGFR;…”
Get full text

Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3‐Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations by Bardia, Aditya, Gounder, Mrinal, Rodon, Jordi, Janku, Filip, Lolkema, Martijn P., Stephenson, Joe J., Bedard, Philippe L., Schuler, Martin, Sessa, Cristiana, LoRusso, Patricia, Thomas, Michael, Maacke, Heiko, Evans, Helen, Sun, Yongjian, Tan, Daniel S.W.

“…Background This multicenter, open‐label, phase Ib study investigated the safety and efficacy of binimetinib (MEK inhibitor) in combination with buparlisib…”
Get full text

Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer by Stephenson, Joe J, Nemunaitis, John, Joy, Anil A, Martin, Julie C, Jou, Ying-Ming, Zhang, Da, Statkevich, Paul, Yao, Siu-Long, Zhu, Yali, Zhou, Honghong, Small, Karen, Bannerji, Rajat, Edelman, Martin J

“…Abstract Objectives Dinaciclib (MK-7965, formerly SCH 727965), a novel, small-molecule inhibitor of cyclin-dependent kinases, has been shown to induce…”
Get full text

An Open-Label, Phase II Study of the Polo-like Kinase-1 (Plk-1) Inhibitor, BI 2536, in Patients with Relapsed Small Cell Lung Cancer (SCLC) by Awad, Mark M, Chu, Quincy S-C, Gandhi, Leena, Stephenson, Joe J, Govindan, Ramaswamy, Bradford, Daniel S, Bonomi, Philip D, Ellison, David M, Eaton, Keith D, Fritsch, Holger, Munzert, Gerd, Johnson, Bruce E, Socinski, Mark A

“…Highlights • BI 2536 inhibits polo-like kinase 1 (Plk-1), a critical regulator of the cell cycle. • Plk inhibitors prevent growth of several small cell lung…”
Get full text

Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours by Devriese, Lot A., Koch, Kevin M., Mergui-Roelvink, Marja, Matthys, Gemma M., Ma, Wen Wee, Robidoux, Andre, Stephenson, Joe J., Chu, Quincy S. C., Orford, Keith W., Cartee, Leanne, Botbyl, Jeff, Arya, Nikita, Schellens, Jan H. M.

“…Summary Aim To quantify the effect of food on the systemic exposure of lapatinib at steady state when administered 1 h before and after meals, and to observe…”
Get full text

A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy by Ramanathan, Ramesh K., Stephenson, Joe J., Weiss, Glen J., Pestano, Linda A., Lowe, Ann, Hiscox, Alton, Leos, Rafael A., Martin, Julie C., Kirkpatrick, Lynn, Richards, Donald A.

“…Summary Purpose This phase I trial assessed the safety, dose limiting toxicity (DLT) and pharmacodynamics of PX-12 in adult patients with advanced refractory…”
Get full text

A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies by Gerecitano, John F., Stephenson, Joe J., Lewis, Nancy L., Osmukhina, Anna, Li, Jianguo, Wu, Kaida, You, Zhiping, Huszar, Dennis, Skolnik, Jeffrey M., Schwartz, Gary K.

“…Summary Background This Phase I study assessed the safety and maximum tolerated dose (MTD) of the kinesin spindle protein inhibitor AZD4877 in patients with…”
Get full text

An Open-Label Clinical Trial Evaluating Safety and Pharmacokinetics of Two Dosing Schedules of Panitumumab in Patients with Solid Tumors by Stephenson, Joe J, Gregory, Charles, Burris, Howard, Larson, Tim, Verma, Udit, Cohn, Allen, Crawford, Jeffrey, Cohen, Roger B, Martin, Julie, Lum, Peggy, Yang, Xinqun, Amado, Rafael G

“…Abstract Purpose This study evaluated safety, pharmacokinetics, and efficacy of 2 dose schedules and 2 infusion times of panitumumab in patients with advanced…”
Get full text

A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response by Rifkin, Robert M., Greenspan, Andrew, Schwerkoske, John F., Mandanas, Romeo A., Stephenson, Joe J., Kannarkat, George T., Zhan, Feng, Boehm, Kristi A., Asmar, Lina, Beveridge, Roy

“…Summary Background A majority of multiple myeloma (MM) patients fail to achieve complete response (CR) to peripheral blood stem cell transplantation (PBSCT);…”
Get full text

Abstract B185: Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor E7016 in combination with temozolomide (TMZ) in patients with advanced solid tumors by Mita, Alain C., Mita, Monica M., Sarantopoulos, John, Martin, Julie C., Kueber, Janet D., McGonigle, Sharon, Matijevic, Mark, Mistry, Bipin, Ferrada, Javier L., Sachdev, Pallavi, Stephenson, Joe J.

“…Abstract Background: E7016 is an orally bioavailable, nicotinamide mimetic PARP1 and PARP2 inhibitor. E7016 was shown to enhance the cytotoxic effect of the…”
Get full text

Abstract A88: Safety, pharmacokinetic, and pharmacodynamic results of BAY 86–9766, an oral MEK inhibitor, in combination with sorafenib, an oral multikinase inhibitor, in advanced cancer patients by Adjei, Alex A., Richards, Donald A., El-Khoueiry, Anthony, Becerra, Carlos H.R., Stephenson, Joe J., Leffingwell, Diane P., Iverson, Cory, Miner, Jeffrey N., Shen, Zancong, Gunawan, Sonny, Wilson, David, Manhard, Kimberly J., Dubowy, Ron L., Jeffers, Michael, Rajagopalan, Prabhu, Franklin, Wilbur A., Haney, Jerry, Lenhart, Patricia, Clendeninn, Neil J.

“…Abstract Background: Preclinical data revealed a synergistic interaction between sorafenib (Nexavar®) and BAY 86-9766 (RDEA119). Sorafenib is an oral, small…”
Get full text

A Phase II Study of Xcellerated T Cells™ in Patients with Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma (NHL) by Bartlett, Nancy L., Gribben, John G., Boccia, Ralph V., Milder, Michael S., Aboulafia, David M., Castro, Januario, Flinn, Ian, Hayes-Lattin, Brandon, Kaplan, Lawrence, Lin, Thomas, Lucas, Jennifer B., Maloney, David G., McLaughlin, Peter, McSweeney, Peter A., Mohrbacher, Ann, Redfern, Charles, Steis, Ronald, Stephenson, Joe J., Strair, Roger, Berenson, Ronald J., Frohlich, Mark W.

“…Background: T cells can be activated and expanded ex vivo using the Xcellerate™ Process, in which peripheral blood mononuclear cells (PBMC) are incubated with…”
Get full text

Idarubicin-induced pigmentary changes of the nails by Borecky, D J, Stephenson, J J, Keeling, J H, Vukelja, S J

“…A case of acute myelocytic leukemia of the FAB-M2 subtype in a patient who experienced pigmentary nail changes in conjunction with idarubicin therapy is…”
Get more information